Enflicoxib (Daxocox) Once-Weekly Dosing: Field Efficacy and Compliance Rationale

TL;DR

Enflicoxib (Daxocox) is the only once-weekly NSAID authorised by the EMA for canine osteoarthritis, and field data from a 12-week pivotal study suggest responder rates in the 70-75% range, comparable to daily NSAIDs, with an adverse-event profile consistent with the class.

What just dropped

• A randomised, controlled, blinded field study in 109 dogs with chronic osteoarthritis signs found that enflicoxib produced CSS (Canine Symptom Score) responder rates of 71.6%, 74.6%, and 71.6% at weeks 4, 8, and 12 respectively, compared to placebo rates of 41.7%, 33.3%, and 20.8%. The difference was statistically significant (p less than 0.05) at all time points. Adverse events were consistent with other NSAIDs used in dogs. (https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2024.1349901/full)
• EMA authorised enflicoxib for once-weekly oral treatment of pain and inflammation associated with osteoarthritis in dogs under the trade name Daxocox. EPAR reference EMEA/V/C/005354. (https://www.ema.europa.eu/en/medicines/veterinary/EPAR/daxocox)

Context

Daily oral NSAID administration is a cornerstone of long-term osteoarthritis management in dogs, but owner compliance with daily medication is a recognised challenge in chronic disease management. Enflicoxib is a COX-2-selective NSAID that reaches tissue concentrations sufficient for once-weekly dosing due to its distribution characteristics. EMA granted marketing authorisation for Daxocox under EMEA/V/C/005354, making it the only licensed once-weekly NSAID for canine osteoarthritis in Europe.

The pivotal field study enrolled 109 dogs in a 3:1 active-to-placebo ratio across multiple clinical sites. The Canine Symptom Score (CSS), a multidimensional clinical assessment tool, was the primary outcome measure. Responder rates in the enflicoxib group (approximately 71-75%) were consistent with those reported for daily NSAID comparators in similar populations, with a statistically significant benefit over placebo at all assessment time points through 12 weeks. The adverse-event profile did not differ substantively from other NSAIDs used in dogs, with gastrointestinal signs being the predominant class-associated risk.

What this changes in Enflicoxib (Daxocox) for Canine Osteoarthritis (https://www.thevoyage.ai/forvets/knowledge/enflicoxib-daxocox-canine-osteoarthritis)

For clinicians managing dogs where daily pill administration is a compliance barrier (e.g., fractious patients, owners with physical limitations, multidog households requiring individual dosing), enflicoxib's once-weekly schedule offers a practical option without sacrificing evidence-supported efficacy compared to placebo. The field study responder rates are not directly comparable to head-to-head trials against daily NSAIDs, so prescribers should not assume equivalence to daily meloxicam or carprofen without reviewing available comparative data. Renal and hepatic pre-treatment screening and ongoing monitoring follow the same NSAID class principles. All NSAID selection and monitoring should follow current WSAVA guidelines and product labelling.

Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=enflicoxib-daxocox-canine-osteoarthritis

References

1. Salichs M et al. 2024. Field efficacy and safety of enflicoxib in dogs with chronic osteoarthritis pain: a randomised, blinded, placebo-controlled study. Front Vet Sci 11:1349901. https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2024.1349901/full
2. EMA. 2021. Daxocox (enflicoxib) EPAR. EMEA/V/C/005354. CVMP positive opinion 19/02/2021. https://www.ema.europa.eu/en/medicines/veterinary/EPAR/daxocox

---

Related reads

• Enflicoxib (Daxocox) for Canine Osteoarthritis: A Once-Weekly COX-2 Selective NSAID